These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 11879771)

  • 1. Medicinal chemistry and therapeutic potential of CpG DNA.
    Agrawal S; Kandimalla ER
    Trends Mol Med; 2002 Mar; 8(3):114-21. PubMed ID: 11879771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and therapeutic applications of immune stimulatory cpG DNA.
    Krieg AM; Yi AK; Hartmann G
    Pharmacol Ther; 1999 Nov; 84(2):113-20. PubMed ID: 10596901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards optimal design of second-generation immunomodulatory oligonucleotides.
    Kandimalla ER; Yu D; Agrawal S
    Curr Opin Mol Ther; 2002 Apr; 4(2):122-9. PubMed ID: 12044033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
    Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.
    Agrawal S; Kandimalla ER
    Ann N Y Acad Sci; 2003 Dec; 1002():30-42. PubMed ID: 14751820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma.
    Carpentier AF; Auf G; Delattre JY
    Front Biosci; 2003 Jan; 8():e115-27. PubMed ID: 12456326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.
    Klimek L; Bachmann MF; Senti G; Kündig TM
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1059-67. PubMed ID: 24898577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA.
    Yu D; Kandimalla ER; Zhao Q; Bhagat L; Cong Y; Agrawal S
    Bioorg Med Chem; 2003 Feb; 11(3):459-64. PubMed ID: 12517441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
    Harandi AM; Holmgren J
    Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects for CpG based immunotherapy in asthma and allergy.
    Broide DH
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2006; (95):217-20; discussion 220-2. PubMed ID: 17393743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans.
    Davis HL; Suparto II; Weeratna RR; Jumintarto ; Iskandriati DD; Chamzah SS; Ma'ruf AA; Nente CC; Pawitri DD; Krieg AM; Heriyanto ; Smits W; Sajuthi DD
    Vaccine; 2000 Mar; 18(18):1920-4. PubMed ID: 10699341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG DNA: a novel immunomodulator.
    Krieg AM
    Trends Microbiol; 1999 Feb; 7(2):64-5. PubMed ID: 10081082
    [No Abstract]   [Full Text] [Related]  

  • 15. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA.
    Krieg AM
    Antisense Nucleic Acid Drug Dev; 2001 Jun; 11(3):181-8. PubMed ID: 11446594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CpG dinucleotides in DNA vaccines.
    Krieg AM; Yi AK; Schorr J; Davis HL
    Trends Microbiol; 1998 Jan; 6(1):23-7. PubMed ID: 9481820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
    Weiner GJ
    J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma.
    Ursu R; Carpentier AF
    Adv Exp Med Biol; 2012; 746():95-108. PubMed ID: 22639162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostimulatory oligonucleotides: ready for immunotherapy prime time!
    Tam YK
    J Hematother Stem Cell Res; 2003 Oct; 12(5):467-71. PubMed ID: 14594503
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.